October 27, 2025 – Insilico Medicine, a clinical-stage generative AI-powered drug discovery company, today announced its participation in the upcoming BIO-Europe conference, taking place November 3–5, 2025, in Vienna, Austria. At the event, Insilico will introduce its emerging Cardiometabolic Portfolio and showcase the capabilities of its end-to-end Pharma.AI platform.

Alex Zhavoronkov, PhD, Founder and CEO of Insilico, will be a featured speaker in a panel discussion scheduled for Tuesday, November 4, 2025, from 15:00 to 15:30, where he will discuss how generative AI is accelerating the development of new therapies for age-related diseases. Meanwhile, the company's business development team will be available for meetings at the booth, as well as through the conference's partnering system, to pursue strategic collaborations.

"BIO-Europe is a premier event for fostering the collaborations that drive biotech innovation," said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. "This year, we are excited to introduce our emerging cardiometabolic portfolio, featuring novel programs targeting diseases closely linked to the aging process. We look forward to engaging with industry leaders and demonstrating how our Pharma.AI platform is accelerating the discovery of novel therapeutics. Our goal is to forge partnerships that will help enable longer, healthier lives for people around the world."

Since pioneering next-generation AI in drug discovery, Insilico Medicine has built an extensive therapeutic portfolio across high-demand areas, rapidly advancing its internal R&D pipeline and setting a new standard for efficiency. While traditional early-stage drug discovery can take 2.5 to 4 years, Insilico has nominated 20 preclinical candidates at an average pace of just 12 to 18 months per program, synthesizing and testing only 60 to 200 molecules each—highlighting the exceptional capabilities of its AI-driven platform.

Among the company's clinical-stage programs, Rentosertib, the world's first AI-discovered novel-mechanism anti-fibrotic candidate, has completed Phase 2a proof-of-concept clinical trial, demonstrating promising efficacy trends and a favorable safety profile. ISM5411, the PHD1/2 inhibitor with best-in-class potential for treating inflammatory bowel disease (IBD) has completed 2 Phase 1 trials, showing good safety and gut-restrictedPK profile. Additionally, three of Insilico's anti-tumor programs have now reached the first-in-patient dosing stage, and interim results are expected to be shared in the near future.

Earlier this year at BIO-US, Insilico introduced its early-stage pipeline in oncology, metabolism, and pain management. Several promising candidates are currently in the lead compound optimization phase. The full pipeline is available at https://insilico.com/pipeline.

Since founding in 2014, Insilico has published over 200 peer-reviewed papers. Leveraging sustained scientific breakthroughs at the intersection of biotechnology, artificial intelligence, and automation, Insilico ranked Top 100 global corporate institutions in Nature Index's "2025 Research Leaders: global corporate institutions for biological sciences and natural sciences publications".

Reference

[1] Fu, Y., Ding, X., Zhang, M. et al. Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor. Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02503-w

[2] Ren, F., Aliper, A., Chen, J. et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02143-0

[3] Xu, Z., Ren, F., Wang, P. et al. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nat Med 31, 2602–2610 (2025). https://doi.org/10.1038/s41591-025-03743-2

About Insilico Medicine

Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.

For more information, visit www.insilico.com.